Go to the list of all blogs
Allana's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
Greenwich LifeSciences (GLSI) Reports Wider Q3 Net Loss on Rising Trial Costs

Greenwich LifeSciences (GLSI) Reports Wider Q3 Net Loss on Rising Trial Costs

Key Takeaways

  • Greenwich LifeSciences reported a net loss of $5.81 million for the third quarter of 2026, up from $3.71 million in the prior-year period.
  • Loss per share widened to $0.40, compared with $0.27 a year earlier and below the consensus estimate of approximately $0.34.
  • The company generated no revenue in the quarter, consistent with its status as a pre-revenue clinical-stage biopharmaceutical developer.
  • Research and development (R&D) expenses climbed roughly 67% year over year, driven by expansion of the Flamingo-01 Phase 3 clinical trial for the GP2 immunotherapy.
  • Management flagged a going concern warning, with a cash balance of about $5.9 million and continued reliance on at-the-market (ATM) equity offerings.
  • For additional context, you can review Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
  • Explore Trending AI Robots to see AI-driven trading strategies currently attracting investor attention.

Putting the Earnings in Context

GLSI is a clinical-stage company focused on GP2, an immunotherapy candidate aimed at preventing breast cancer recurrence after surgery. With no approved products yet, these reports matter mainly for insights into clinical progress, spending patterns, and how long the cash will last. The Flamingo-01 Phase 3 trial is the main value driver, so its cost trajectory directly affects the runway. The wider loss per share and higher R&D outlay this quarter give a clear signal on trial execution and funding sustainability through what could be a long regulatory process.

Breaking Down the Reported Numbers

For the third quarter ended September 30, 2026, GLSI posted a net loss of $5.81 million versus $3.71 million in the same quarter last year. Basic and diluted loss per share came in at $0.40, compared with $0.27 previously. Over the first nine months, the net loss reached $15.42 million, up from $10.2 million, with loss per share at $1.05 versus $0.76. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

The $0.40 loss per share missed the roughly $0.34 consensus estimate. Revenue remained zero, as expected for this pre-revenue profile. The bigger loss stemmed mainly from the 67% year-over-year jump in R&D tied to Flamingo-01, plus a cash position of about $5.9 million that prompted the going-concern note and ongoing ATM use.

Market Reaction and Sentiment

Sentiment was already measured heading into the release because of the rising burn rate and tight balance sheet. The wider loss and going-concern disclosure added to worries about near-term dilution via the ATM. Without revenue to support valuation, the share price reacts more to financing updates and trial milestones than to standard earnings beats. Discussion after the report has focused on whether faster Flamingo-01 enrollment offsets the higher spend and how future raises might affect existing holders.

Forward Outlook and Factors to Watch

The key item remains execution on the Flamingo-01 Phase 3 trial. As enrollment grows, R&D will likely keep driving expenses, so investors will want to see whether trial momentum points to clearer data timelines.

Cash runway comes next. With roughly $5.9 million on hand and a nine-month operating burn near $9.6 million, continued ATM access or other financing looks probable. Dilution effects, raise terms, and management comments on capital will influence sentiment.

Finally, monitor GP2 updates on clinical progress, regulatory steps, and any partnership talks that could ease funding pressure. For a pre-revenue biotech, catalysts and financing decisions outweigh quarterly profits in the periods ahead. I’m watching this closely as trial data and capital moves unfold.

AI Tools in My Research Routine

When reviewing clinical-stage names like GLSI, I often turn to Tickeron’s AI Screener to quickly compare peers and spot technical patterns. It streamlines scanning for similar opportunities and helps keep track of sector shifts without hours of manual work. This kind of resource has become a regular part of how I evaluate biotech setups and stay informed on comparable names.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: GLSI

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


GLSI in downward trend: price expected to drop as it breaks its higher Bollinger Band on November 18, 2026

GLSI broke above its upper Bollinger Band on November 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 40 similar instances where the stock broke above the upper band. In 35 of the 40 cases the stock fell afterwards. This puts the odds of success at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The 10-day moving average for GLSI crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GLSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for GLSI entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on GLSI as a result. In 77 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.

The Moving Average Convergence Divergence (MACD) for GLSI just turned positive on November 17, 2026. Looking at past instances where GLSI's MACD turned positive, the stock continued to rise in 42 of 45 cases over the following month. The odds of a continued upward trend are 90%.

GLSI moved above its 50-day moving average on November 17, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +49.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where GLSI advanced for three days, in 213 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. GLSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: GLSI's P/B Ratio (71.438) is slightly higher than the industry average of (3.596). P/E Ratio (-9.541) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GLSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -12%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 105%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 84%. For the same stocks of the Industry, the average monthly volume growth was 101% and the average quarterly volume growth was 38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
3992 Bluebonnet Drive
Phone
+1 832 819-3232
Employees
13
Web
https://www.greenwichlifesciences.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.